TRAIL peptide

GeneTex

TRAIL peptide

9

The peptide is used for blocking the activity of anti-TRAIL. Incubatingthe peptide with equal volume of antibody for 30 min at 37C usually completely blocks theactivity of anti-TRAIL (GTX22056) in Western blotting.

Neutralisation/Blocking

Research Use Only

0.20 mg/ml

Unconjugated

TNFSF10

TNF superfamily member 10

APO2L, Apo-2L, CD253, TANCR, TL2, TNLG6A, TRAIL, tumor necrosis factor ligand superfamily member 10, Apo-2 ligand, TNF-related apoptosis inducing ligand TRAIL, chemokine tumor necrosis factor ligand superfamily member 10, tumor necrosis factor (ligand) family, member 10, tumor necrosis factor (ligand) superfamily, member 10, tumor necrosis factor ligand 6A, tumor necrosis factor superfamily member 10

Apoptosis or programmed cell death is induced in cells by a group of death domain containing receptors. Binding of ligand to these receptors sends signals that activate members of the caspase family of proteases. The signals ultimately cause degradation of chromosomal DNA by activating DNase. TRAIL (TNF related apoptosis induced ligand) or Apo 2L initiates apoptosis of tumor cells by binding to either of its receptors, DR4 or DR5. These receptors consist of an extracellular TRAIL binding domain and a cytoplasmic death domain. In addition, two decoy receptors for TRAIL have also been identified. These receptors, designated DcR1 and DcR2, lack the death domain. Binding of TRAIL to either of these receptors, therefore, does not transmit the death signal. Thus, these receptors represent a novel way of regulating cell sensitivity to a pro-apoptotic cytokine at the cell surface. TRAIL is expressed predominantly in spleen, lung, and prostate but also in many other tissues.

-20°C

41116100

Human